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platelet number was 198000 in high, and 213000 in low-
intermediate group. Out of 35 patients who were checked
for both HCVRNA and Anti-HCV 68.5% (n = 24) positive for
both Anti-HCV and HCVRNA, while 31.5% were positive for
anti-HCV but HCVRNA negative. These patients are believed
to be immune to HCV.
Conclusion: With the introduction of HCV quantiﬁcation
method as a diagnostic tool, it became possible to
distinguish truly HCV immune patients who were considered
as HCV infected before. We noticed positive correlation HCV
viral load with liver enzymes. The method allows treatment
monitoring for the ﬁrst time in Mongolia.
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Aim: Prediction of main side effects of chronic hepatitis C
treatment with Peg-IFN a2a and ribavirin.
Methods: We evaluated in 55 patients treated with
Peg-IFN a-2a plus ribavirin numerous predictors inﬂuence
on main side effects (dichotomous dependent variable) on
different date of therapy: ﬂu-like syndrome, leucopenia,
thrombocytopenia, weigh lose, fatigue, depression,
insomnia, artralgia, myalgia, anorexia, nausea, anemia,
headache, alopecia, pruritus and rash. Statistic analyses
was done by SPSS 11.0 with binary logistic regression. Eleven
independent variables, such as age, gender, body mass in-
dex (BMI), disease limitation, pretreatment with standard or
Peg-IFN, presence of antibodies to HBV, alcohol abuse, drug
abuse, genotype (1b, 1a, 2 and 3), level of ferritin (FERR),
viral load (VL), were coding as dichotomous or categorical.
Results: Already on ﬁrst month of the treatment probability
of myalgia calculated by formula 1:
log
p
1 p
= 1.33 1.34HBV(1)
3.32 disease limitation(1)
2.64 disease limitation(2),
(1)
where HBV(1) HBcAb; disease limitation(1) long-standing
of HCV-infection up to 5 years; disease limitation(2) 5 10
years. Probability of ﬂu-like syndrome on ﬁrst month of
therapy is calculated by formula 2:
log
p
1 p
= 2.54
+ 2.69 genotype 1a
+ 8.07 genotype 2
+ 2.38 genotype 3
+ 2.67 high VL
1.94 alcohol abuse.
(2)
Risk factors were genotype 1a (OR = 14.7) and highVL
(OR = 1.45).
Signiﬁcant model was received for IVDU (p = 0.005), alcohol
abuse, HBV infection, high FERR and VL inﬂuence on weight
loss during last months of therapy (formula 3):
log
p
1 p
= 1.73 4.36 IVDU 1.78 high FERR
0.038 high VL 0.096 alcohol abuse
+ 1.55HBcAb.
(3)
Conclusions: Development of side effects of the treatment
with pegylated IFN-alfa-2a and ribavirin depends on some
predictor factors.
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Introduction: There is a growing evidence of intergenotypic
recombination in HCV. In this paper we report a patient
infected by HCV 1b and, probably, recombinant 2/1b that is
detected in peripheral blood mononuclear cells (PBMC).
Case description: Patient S., male, 31 years old admitted
in January 2009. HCV viral load in serum before treatment
9,630,000 IU/ml. HCV genotyping by sequencing 5′UTR and
NS5A. According to phylogenetic analysis NS5A belongs to 1b
(sera and PMBC), 5′UTR from serum to 1b, from PBMC to
genotype 2. Due to discordant results recombinant 2/1b
in PBMC can be suspected. NS5A interferon sensitivity
determining region (ISDR) contains mutation R2218H.
Laboratory: ALT 71U/l, AST 62U/l, GGT 36U/l. Liver
biopsy: HAI 8, ﬁbrosis 1. Immunohistochemically HCV NS3
was detected in lobules and tracts. Elevated CD16 and
CD20 was found in lymphoid follicules of portal tracts.
Patient received treatment with pegintron (1.5mg/kg BW)
plus ribavirin (1000mg/day) for 48 weeks. Virological and
biochemical response were achieved on 12 wk and remained
until the end of treatment and during follow-up. Liver biopsy
after treatment: HAI 3, ﬁbrosis 0. Immunohistochemically
NS3 was still detected in lobules and tracts, CD16 and CD20
decreased in portal tracts.
